FLT3 and acute myeloid leukemia: Molecularly, AML is mainly characterized by Nuclear-cytoplasmic shuttling phosphoprotein (NPM1) mutation and by FMS-like tyrosine kinase 3 (Flt3), a Class III receptor tyrosine kinase, genetic alterations that include internal tandem duplication (FLT3-ITD) tyrosine kinase domain amino acid substitution (FLT3-TKD) and promising molecular therapeutics target [22].